Frequency Therapeutics Inc (FREQ) Stock
FREQ is no longer traded. Frequency Therapeutics was delisted from the Nasdaq in November 2023.
Prices on this page are historical; the last trade was November 3, 2023 at $0.30.
Frequency Therapeutics stock price history
FREQ final trading statistics
- Final close
- $0.30
- Final trading day
- Nov 3, 2023
- Market cap at delisting
- $10.94M
- Shares outstanding
- 36.52M
- Final 52-week range
- $0.18 – $5.59
- Avg. volume (final 3 mo.)
- 159,345
- All-time high (split-adj.)
- $2750.50 · Feb 2021
- All-time low (split-adj.)
- $10.82 · Oct 2023
- Return since IPO
- -97.8%
- Beta
- 0.77
- Book value / share
- $0.99
- Price / book
- 0.30
Frequency Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$81.6M | -$2.32 |
| FY2021 | $14.07M | -$84.7M | -$2.47 |
| FY2020 | $36.98M | -$26.5M | -$0.81 |
| FY2019 | $28.95M | -$16.0M | -$7.59 |
| FY2018 | $0.00 | -$19.2M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Frequency Therapeutics Inc
As of November 3, 2023, Frequency Therapeutics, Inc. was acquired by Korro Bio, Inc., in a reverse merger transaction. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Frequency Therapeutics stock FAQ
What happened to Frequency Therapeutics stock?
Frequency Therapeutics stock was delisted from the Nasdaq. Its final close was $0.30 on November 3, 2023.
Is FREQ stock still trading?
No. FREQ was delisted from the Nasdaq in November 2023 and no longer trades on a U.S. exchange.
What was the last price of FREQ stock?
FREQ closed at $0.30 on its final trading day, November 3, 2023, for a market value of about $10.94M.
What were Frequency Therapeutics's revenue and earnings in its last full fiscal year?
Frequency Therapeutics reported revenue of $0.00 and net income of -$81.6M in fiscal 2022, its last full year as a public company.
When did Frequency Therapeutics go public?
Frequency Therapeutics Inc stock began trading on October 3, 2019.